Suboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI study.

Objectives: Methotrexate (MTX) is the first choice in the treatment of rheumatoid arthritis (RA), but the doses and regimens vary significantly. For this purpose, we conducted an observational study on the use of MTX for RA in Italy (MARI study).

Methods: The MARI study included 1,327 RA patients on MTX treatment for at least 12 months, at 60 Italian rheumatology units.

A multicentre comparison of flurbiprofen and naproxen in rheumatoid arthritis: a four-week study in 118 patients.

One-hundred and eighteen patients with rheumatoid arthritis were treated for 4 weeks with flurbiprofen 300 mg/day (sixty patients) or naproxen 750 mg/day (fifty-eight patients) in a six-centre randomized trial. Flurbiprofen proved to be more effective than naproxen in reducing morning stiffness (p less than 0.01), Ritchie articular index (p less than 0.